Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol describes a unique method for constructing an orthotopic model of superficial bladder cancer.

Abstract

This study presents an innovative method for establishing an orthotopic murine bladder tumor model with high efficiency and precise tumor localization. After anesthetizing female C57BL/6J mice in a supine position, a 24 G intravenous needle is inserted into the bladder to evacuate its contents. A 34 G dispensing needle is then introduced through the catheter, rotated five times to create a focal injury to the bladder dome mucosa, and subsequently removed. The MB49 cell suspension is aspirated and connected to a 30 G dispensing needle, which is inserted into the bladder via the catheter. Tumor cells are injected submucosally into the bladder under pressure. This technique results in minimal trauma to the mice, a high tumor take rate, and a fixed tumor location. It is characterized by simplicity and excellent reproducibility. This model provides an ideal experimental platform for developing intravesical therapies for bladder cancer, facilitating the advancement and optimization of treatment strategies for this malignancy.

Introduction

Bladder cancer represents a significant global health burden, with notable sex-specific disparities in incidence and prognosis. This malignancy is characterized by distinct molecular subtypes, each associated with diverse pathogenic pathways. The molecular and pathological features differ significantly between non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC)1,2. NMIBC accounts for approximately 75% of cases, featuring tumors of transitional epithelial origin that remain localized without metastasis or spread. Conversely, MIBC is characterized by the infiltration of cancer ce....

Protocol

All animal experimental protocols and procedures were approved by the Ethical Review Committee for Animal Experimentation of Tianjin Medical University, Tianjin, China (approval number SYXK: 2020-0010). Six- to eight-week-old female C57BL/6J mice were used for this study. The animals were housed under controlled environmental conditions, including a 12-h light-dark cycle, temperatures ranging from 21-25 °C, adjustable humidity levels between 30%-70%, and unrestricted access to food and water unless otherwise specifi.......

Representative Results

The efficacy of submucosal injections was initially assessed through the administration of Trypan Blue. Post-injection, the dye's distribution within the submucosal layer was clearly visualized, confirming the precise and controlled delivery of the injected substances (Figure 1).

Tumor development was meticulously tracked. Approximately 14 days post-implantation, a notable incidence of hematuria was observed, a critical symptom indicative of bladder neoplasia........

Discussion

Research on bladder cancer relies on animal models, which are indispensable for both basic and applied research. To better mimic the tumor growth environment, orthotopic bladder tumor models provide a superior approach compared to subcutaneous tumor models11.

Currently, orthotopic bladder cancer models can be categorized based on experimental purposes into two main types: those utilizing immunodeficient mice, such as patient-derived xenograft (PDX) models

Acknowledgements

This study was supported by the Tianjin Municipal Health Industry Key Project fund (grant no. TJWJ2022XK014), the Scientific Research Project fund of Tianjin Municipal Education Commission (grant no. 2022ZD069), the Tianjin Institute of Urology Talent Funding Program (grant no. MYSRC202310), the Clinical Medicine Research Project fund of the Second Hospital of Tianjin Medical University (grant no. 2023LC03), the Youth Fund of the Second Hospital of Tianjin Medical University (grant no. 2022ydey15), and the Talent Cultivation Project of the Department of Urology, the Second Hospital of Tianjin Medical University (grant no. MNRC202313). The sponsors played a role in the....

Materials

NameCompanyCatalog NumberComments
34 G dispensing needleSuzhou Haorun Fluid Technology Co., Ltd., Suzhou, ChinaSGL-362
30 G dispensing needleSuzhou Haorun Fluid Technology Co., Ltd., Suzhou, ChinaSGL-362
AvertinSigma-Aldrich LLCT48402
Trypan blueSigma-Aldrich LLC302643

References

  1. Tran, L., Xiao, J. F., Agarwal, N., Duex, J. E., Theodorescu, D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 21 (2), 104-121 (2021).
  2. Dyrskjøt, L., et al. Bladder cancer. Nat Rev Dis Primers. 9 (1), 58 (2023).
  3. Si....

Explore More Articles

Murine Bladder Cancer ModelIntravesical Cell AdministrationOrthotopic Bladder TumorC57BL 6J MiceMB49 Cell SuspensionFocal InjurySubmucosal InjectionTumor Take RateExperimental PlatformIntravesical TherapiesBladder Cancer Treatment Strategies

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved